Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.919
+0.047 (5.39%)
At close: Feb 21, 2025, 4:00 PM
0.880
-0.039 (-4.23%)
After-hours: Feb 21, 2025, 7:59 PM EST
Imunon Employees
Imunon had 33 employees as of December 31, 2023. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$589,429
Market Cap
13.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
IMNN News
- 2 days ago - IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - GlobeNewsWire
- 3 days ago - IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewsWire
- 12 days ago - IMUNON Appoints Douglas V. Faller, M.D. - GlobeNewsWire
- 2 months ago - IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewsWire
- 2 months ago - IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - GlobeNewsWire
- 3 months ago - IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer - GlobeNewsWire
- 3 months ago - Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire